BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

With regional differences in which name is used for the aortic fix, some say unity is needed. Others can live with both.

Capstan Medical’s robot platform has been used for the first in-human robotic assisted transcatheter mitral valve replacement procedures, confirming the company’s credentials in joining the ...

C Medical Technologies has closed its Series D financing round, raising gross proceeds of up to $175m. Led by Boston ...

A new transcatheter valve, the Trilogy system, has demonstrated safety and efficacy in treating aortic regurgitation, with a one-year mortality rate of 8.1%, surpassing the trial's goal of 25%.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial ...

The mitral valve is the most commonly repaired ... Non-surgical procedures to treat valvular disease, such as transcatheter aortic valve replacement (TAVR), provide additional treatment options ...

The largest markets for these devices include aortic and mitral valve replacements. The transcatheter tricuspid valve device market is both newer and smaller, mostly due to the lower number of ...

Growing investments in healthcare infrastructure and advancements in medical research facilities are driving the expansion of cardiac valve repair devices in the Middle East and Africa (MEA) region.

Transcatheter valve replacement technologies have been displacing open-heart valve surgical procedures worldwide in recent years.